NGENFNervGen Pharma Corp.

About NervGen Pharma Corp. (NGENF)

NervGen Pharma Corp. (NGENF) is a Biotechnology company headquartered in Vancouver, BC, Canada whose shares trade over-the-counter on the OTCQB tier.

NervGen Pharma Corp. is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen's lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company's initial target indication, spinal cord injury. NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma (PTPσ). NVG-291 has received Fast Track designation in spinal cord injury from the U.S. Food and Drug Administration. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Products and services

Research and development of pharmaceutical products. No commercial products approved.

NGENF key facts

Ticker symbol

NGENF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Vancouver, BC, Canada

Country of incorporation

CA

Year of incorporation

2017

Employees

14

Estimated market cap

$144.19M (as of Apr 9, 2025)

Shares outstanding

71,027,649

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Interim Financial Report (Sep 30, 2024)

NervGen Pharma Corp. leadership

• Michael Kelly — CEO
• William Adams — CFO
• Daniel Mikol — CMO
• Barbara Richard — Executive Assistant
• Accounts Payable — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with N